Faster, cheaper & safer monoclonal antibody production
Imagine developing a life-saving biologic, only to realize that millions of patients may never access it because manufacturing is too complex and the drug too expensive.
This is the challenge of monoclonal antibodies, a $300B market.
These therapies rely on living cells, and the manufacturing process is still highly manual, requires multiple devices, and carries significant contamination risk.
SW1NGO, is a single-use bioreactor incubator that enables cell culture in 1 go: 1 device, 1 consumable, fully automated. With SW1NGO, we have demonstrated up to 50% cost reduction at global biopharma companies while maintaining the same product quality.
Because the real breakthrough in biologics is making them accessible to everyone who needs them.
